Asceneuron SA today announces the publication of peer-reviewed data in the journal ACS Chemical Neuroscience regarding ASN90, an O–GlcNAcase (OGA) inhibitor, and one of its leading candidates in clinical development for treating neurodegenerative proteinopathies. Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic…

eTurboNews članci su samo za pretplatnike. Pretplata je BESPLATNO.
Pretplatnici se prijavljuju ovdje Kliknite ovdje da se pretplatite BESPLATNO

ŠTO ISKLJUČITI IZ OVOG ČLANKA:

Asceneuron SA danas najavljuje objavu recenziranih podataka u časopisu ACS Chemical Neuroscience o ASN90, inhibitoru O-GlcNAcase (OGA) i jednom od njegovih vodećih kandidata u kliničkom razvoju za liječenje neurodegenerativnih proteinopatija.
Neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease are characterized by the intracellular formation in the brain of insoluble and toxic….
eTurboNews članci su samo za pretplatnike.